在瘤条件下,关于小分子VEGFR抑制剂的最新进展和未来方向
Amandeep Thakur1, Mandeep Rana1, Anshul Mishra1
1School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.
European journal of medicinal chemistry
|May 10, 2024
概括
血管内皮生长因子受体 (VEGFR) 抑制剂在癌症治疗中表现有前途,但面临挑战. 本综述探讨了它们的发展,局限性和改善它们对各种恶性瘤的临床应用的策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 血管内皮生长因子受体 (VEGFR) 抑制剂已经成为癌症治疗中的关键抗血管原体疗法.
- 尽管获得FDA批准,但其临床应用受到并发症和有效性有限的阻碍.
- 目前正在进行的研究重点是提高VEGFR抑制剂从临床前到临床阶段的转化.
研究的目的:
- 在过去十年中,审查VEGFR抑制剂作为癌症治疗药物的进展.
- 分析VEGFR的结构和分子特性,以及生理功能.
- 讨论限制VEGFR抑制剂活性和临床适用性的障碍,并提出克服这些障碍的策略.
主要方法:
- 在癌症治疗中对VEGFR抑制剂的综合文献综述.
- 分析VEGFR的结构/分子特性和生理功能.
- 检查FDA批准的VEGFR抑制剂及其局限性.
- 讨论提高VEGFR抑制剂的疗效和临床应用的策略.
主要成果:
- VEGFR 抑制剂代表着日益增长的一类具有显著治疗潜力的抗血管性疗法.
- 设计了多种结构组合,以利用VEGFR抑制剂的抗增殖潜力.
- 关键障碍包括抵抗机制,毒性和非目标效应,限制它们的活动范围.
结论:
- 在现代瘤学中,VEGFR抑制剂至关重要,但克服它们的局限性对于更广泛的临床成功至关重要.
- 战略设计和组合疗法对于提高VEGFR抑制剂的疗效至关重要.
- 本综述为推进基于VEGFR抑制剂的癌症治疗进入进一步的临床研究提供了见解.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.9K
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
01:24Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K